Dor BioPharma Receives European Patent For Drug Delivery Technology

Dor BioPharma has received a European patent for its Lipid Polymer Micelle (LPM) technology, for the improved oral delivery of drugs.

The issued European patent, EP 1460992, entitled Stabilized Reverse Micelle Compositions and Uses Thereof covers lipid structures, that promote the intestinal absorption of peptides and other sensitive drugs that cannot be given orally.

Christopher Schaber, President and CEO of Dor BioPharma, said: The issuance of the European patent for LPM demonstrates the novelty of this drug delivery system and the preclinical results clearly show that it is a competitive system for oral delivery of drugs, especially those biotechnology products derived from synthetic peptide chemistry or recombinant DNA.”

We also believe that the LPM system will be applicable to a large number of water-soluble drugs including peptides that are poorly permeable, resulting in increased patient compliance and safety, he added.